Subsequent Events	12 Months Ended
Dec. 31, 2021
Subsequent Events
Subsequent Events	Note 7. Subsequent Events On January 28, 2022, the Company received a notification from the Swiss bank that the COVID-19 loan guaranteed by the Swiss Confederation of Chf 168 must be amortized in full within no more than eight years. The start of amortization payments was expected to be paid in March 2022 but has been deferred to September 2022. On January 18, 2022, Mymetics was informed that a patent application was granted by the United States Patent and Trademark Office (“USPTO”). The original patent application (Pub. No. US2020/0170933A1), filed November 26, 2019 and titled “Oral Dispersible Vaccine Comprising Virosomes”, was a joint patent application of Catalent Swindon UK Zydis Ltd. and Mymetics Corporation, which is still pending. A decision was made to submit a US track 1 application via a continuation on August 23, 2021 for a reduced number of the most important claims set forth in the original patent which resulted in this application being granted on January 18, 2022 by the USPTO. On February 22, 2022, Mymetics received the confirmation of acceptance of a publication in Frontiers in Immunology titled “Cooperation between Systemic and Mucosal Antibodies Induced by Virosomal Vaccines Targeting HIV-1 Env: Protection of Indian Rhesus Macaques Against Mucosal SHIV Challenges.” On March 24, 2022, Mymetics received information that a publication was accepted in Nature Scientific Reports in collaboration with the AMC – Amsterdam University Medical Center, titled “A SARS-CoV-2 Wuhan Spike Virosome Vaccine Induces Superior Neutralization Breadth Compared to One Using the Beta Spike.

Subsequent Events

12 Months Ended

Dec. 31, 2021

Note 7. Subsequent Events

On January 28, 2022, the Company received a notification from the Swiss bank that the COVID-19 loan guaranteed by the Swiss Confederation of Chf 168 must be amortized in full within no more than eight years. The start of amortization payments was expected to be paid in March 2022 but has been deferred to September 2022.

On January 18, 2022, Mymetics was informed that a patent application was granted by the United States Patent and Trademark Office (“USPTO”). The original patent application (Pub. No. US2020/0170933A1), filed November 26, 2019 and titled “Oral Dispersible Vaccine Comprising Virosomes”, was a joint patent application of Catalent Swindon UK Zydis Ltd. and Mymetics Corporation, which is still pending. A decision was made to submit a US track 1 application via a continuation on August 23, 2021 for a reduced number of the most important claims set forth in the original patent which resulted in this application being granted on January 18, 2022 by the USPTO.

On February 22, 2022, Mymetics received the confirmation of acceptance of a publication in Frontiers in Immunology titled “Cooperation between Systemic and Mucosal Antibodies Induced by Virosomal Vaccines Targeting HIV-1 Env: Protection of Indian Rhesus Macaques Against Mucosal SHIV Challenges.”

On March 24, 2022, Mymetics received information that a publication was accepted in Nature Scientific Reports in collaboration with the AMC – Amsterdam University Medical Center, titled “A SARS-CoV-2 Wuhan Spike Virosome Vaccine Induces Superior Neutralization Breadth Compared to One Using the Beta Spike.